The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic role of % changes in longest tumor diameter (LTD) in localized high-risk soft tissue sarcoma (STS) treated with neoadjuvant chemotherapy in a randomized clinical trial.
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Carlo Morosi
No Relationships to Disclose
 
Luca Braglia
No Relationships to Disclose
 
Emanuela Palmerini
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Deciphera; EUSA Pharma; EUSA Pharma; Lilly
Research Funding - Daiichi Sankyo; PharmaMar (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Lilly; Takeda
 
Vittorio Quagliuolo
No Relationships to Disclose
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; PharmaMar
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; tesaro
 
Antonella Brunello
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Ipsen; PharmaMar; Takeda
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Pharmamar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Oscar Tendero
No Relationships to Disclose
 
Robert Diaz Beveridge
No Relationships to Disclose
 
Iwona Lugowska
No Relationships to Disclose
 
Valeria Fontana
No Relationships to Disclose
 
Emanuela Marchesi
No Relationships to Disclose
 
Elena Palassini
No Relationships to Disclose
 
Paolo Bruzzi
No Relationships to Disclose
 
Franco Domenico Merlo
No Relationships to Disclose
 
Paolo Giovanni Casali
Consulting or Advisory Role - Bayer; Deciphera
Speakers' Bureau - Pfizer
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar